On February 6, 2018 BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, reported that its Chief Executive Officer, Philip Serlin, will present a company update at the 2018 BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 9:30 am EST (Press release, BioLineRx, FEB 6, 2018, View Source;p=RssLanding&cat=news&id=2330476 [SID1234523741]). The conference will be held at the New York Marriott Marquis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on BioLineRx’s website. A replay will be available one hour after the presentation ends and will be accessible for three months following the presentation.

Investors or potential partners attending the conference who wish to meet with BioLineRx management should contact the BIO Partnering Team at [email protected].

On February 6, 2018 Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, reported that Douglas E. Onsi, Chief Financial Officer, will present a corporate overview at the 20TH Annual BIO CEO & Investor Conference being held at the New York Marriott Marquis in New York City on February 12-13, 2018 (Press release, Leap Therapeutics, FEB 6, 2018, View Source;p=RssLanding&cat=news&id=2330482 [SID1234523761]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

20TH Annual BIO CEO & Investor Conference – Leap Presentation Details:
Date: Tuesday, February 13, 2018
Time: 1:45 P.M. Eastern Time

The presentation will be webcast live and may be accessed on the Investors page of the company’s website at www.investors.leaptx.com, where a replay of the event will also be available for a limited time.

On February 6, 2018 Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases, reported that the Company will present at the 2018 BIO CEO Investor Conference being held February 12 & 13, 2018 at the New York Marriott Marquis, New York (Press release, Cyclacel, FEB 6, 2018, View Source [SID1234523742]). Spiro Rombotis, President & Chief Executive Officer will provide an overview of the Company and its progress in key programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Information on the presentation is as follows:

Event: 2018 BIO CEO Investor Conference
Date: Monday, February 12, 2018
Time: 10:45 am ET
Location: Odets Room, New York Marriott Marquis
A live webcast of the presentation will be available through the Company’s website: www.cyclacel.com. The webcast will be archived for 90 days.

On February 6, 2018 MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, reported that the Company’s management will participate in two upcoming investor conferences (Press release, MacroGenics, FEB 6, 2018, View Source [SID1234523762]). These two conferences include:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SunTrust Robinson Humphrey 2018 Orphan Drug Day — Management will participate in the conference on Tuesday, February 13, 2018, at the JW Marriott Essex House in New York.

Leerink Partners 7th Annual Global Healthcare Conference — Scott Koenig, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat on Thursday, February 15, 2018 at 10:30 am ET at the Lotte New York Palace in New York.

A webcast of the Leerink conference presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at View Source The Company will maintain an archived replay of this webcast on its website for 30 days after the conference.

On February 6, 2018 CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, reported that management will participate in upcoming investor conferences, including the SunTrust Robinson Humphrey 4th Annual Orphan Drug Day and the LEERINK Partners 7th Annual Global Healthcare Conference (Press release, CymaBay Therapeutics, FEB 6, 2018, View Source [SID1234523743]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SunTrust Robinson Humphrey 4th Annual Orphan Drug Day

Date: Tuesday, February 13
Format: One-on-One Format
Location: JW Marriott Essex House, New York City

LEERINK Partners 7th Annual Global Healthcare Conference

Date: Wednesday, February 14
Time: 11:00am Eastern Time
Location: Lotte New York Palace Hotel, New York City
Webcast: View Source